A new drug application of schisandrin and its preparation method for homogeneous suspension

A technology of schisandrin and suspension, which is applied in the direction of drug combination, emulsion delivery, ether/acetal active ingredients, etc., which can solve the problems of many side effects and failure to delay the disease process, achieve obvious preventive effect, and improve animal health. Effects of Behavioral Disorders

Active Publication Date: 2017-08-29
QIQIHAR MEDICAL UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the existing anti-PD drugs such as levodopa are alternative therapies, which can only improve the symptoms to a certain extent, but cannot delay the progress of the disease, and have many side effects after long-term use. PD drugs have become a hot spot in international research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A new drug application of schisandrin and its preparation method for homogeneous suspension
  • A new drug application of schisandrin and its preparation method for homogeneous suspension
  • A new drug application of schisandrin and its preparation method for homogeneous suspension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] 1. Experimental materials

[0020] 1.1 Drugs and reagents

[0021] Schisandrinol (Schisanhenol) was purchased from Chengdu Pusi Biotechnology Co., Ltd. (purity, HPLC>99%). 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, MPTP), purchased from Selegiline In the United States Sigma-Aldrich company. Sodium carboxymethylcellulose (CMC-Na), distributed by Shanghai Chemical Reagent Purchasing and Supply Station.

[0022] 1.2 Experimental Instruments

[0023] Rotating rod instrument: KN-75 type, made in Japan, the diameter of the rotating rod is 2.5cm, and the surface is made of rubber. The test was in a horizontal position and the rotational speed was set at 10 revolutions per minute. Climbing pole: 13 mm diameter, 50 cm high smooth wooden pole with a 3 cm diameter wooden ball on top Developed by Institute of Materia Medica, Chinese Academy of Medical Sciences. The rod is placed vertically during the test.

[0024] 1.3 Expe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new pharmaceutical application of schisanhenol and a preparation method of a homogenized suspension of schisanhenol. The homogenized suspension is used for treating Parkinson disease and expanding the application range of schisanhenol, and also provides a potential drug candidate for the treatment of Parkinson disease. A new preparation method is adopted, which is implemented by preparing schisanhenol into a homogenized suspension, and the homogenized suspension is applied to the oral medication of experimental animals. Animal experiments show that in a MPTP induced parkinson rat model, the schisanhenol homogenized suspension can significantly improve the dyskinesia of experimental animals, and shows a good dose-dependent trend. Concrete embodiments are as follows: compared with a model set, the number of falling of a rat taking the schisanhenol homogenized suspension is significantly reduced, and the incubation period is obviously increased; and the climbing time of a rat detected by using a pole climbing method is significantly shortened, and the dyskinesia score is significantly reduced. The schisanhenol homogenized suspension has a good treatment effect on schisanhenol.

Description

technical field [0001] The invention relates to a new medicine application of schisandrin and a preparation method thereof for a homogeneous suspension. Background technique [0002] Parkinson's disease (PD) is a chronic progressive neurological disease caused by extrapyramidal dysfunction, which is closely related to aging. According to surveys, the incidence rate of the elderly over 60 years old is as high as 1%. With the advent of an aging society, the incidence of PD is increasing. The main clinical symptoms of PD are muscle tremors, stiffness, dyskinesia, and motor balance disorders. In severe cases, daily activities such as eating and dressing are affected. Further development will also lead to recognition, perception, memory impairment, and obvious dementia, which seriously affects the elderly. The health of people has become one of the main problems that plague society and families. Most of the existing anti-PD drugs such as levodopa are alternative therapies, whi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/10A61K31/09A61P25/16
Inventor 李丽波孙超杨宏艳梁鑫朱坤杰
Owner QIQIHAR MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap